Seroquel Off-Label Settlement Puts Clinical Researchers In Spotlight
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca has an agreement in principle to resolve government investigation of its antipsychotic promotion and pay $520 million.
You may also be interested in...
AstraZeneca's Seroquel Settlement With DoJ Is Fourth Targeting Antipsychotic Off-Label Promotion; Firm Avoids Criminal Charges
AstraZeneca's level of cooperation with the Department of Justice's investigation into allegations of off-label promotion for its antipsychotic Seroquel (quetiapine) may have helped shape the final $520 million civil settlement
AstraZeneca's Seroquel Settlement With DoJ Is Fourth Targeting Antipsychotic Off-Label Promotion; Firm Avoids Criminal Charges
AstraZeneca's level of cooperation with the Department of Justice's investigation into allegations of off-label promotion for its antipsychotic Seroquel (quetiapine) may have helped shape the final $520 million civil settlement
AstraZeneca Seroquel Settlement With DoJ Leaves Door Open To Possible Criminal Claims
AstraZeneca's $520 million civil settlement resolves allegations the company promoted Seroquel for off-label uses and provided kickbacks to doctors; DoJ reserves the right to pursue criminal liability claims.